AUA 2019: Diagnostic Efficacy of 18F-RHPSMA7 Positron Emission Tomography for N-staging of Patients with High Risk Primary Prostate Cancer

Chicago, IL ( Retrospective research study was conducted to evaluate 18F radio hybrid prostate specific membrane antigen positron emission tomography (18F-rhPSMA7 PET) for primary N-staging in prostate cancer patients. Previous studies demonstrate that 18F PSNA ligands are superior to the 68Ga- PSMA PET in relation to half-life, negligible urine secretion, and positron range. Further research was needed to estimate 18F-rhPSMA efficacy for the diagnosis of metastatic prostate cancer.

The study team reviewed 18F-rhPSMA PET/CT and PET/MRI scans of high-risk prostate cancer patients who underwent radical prostatectomy with extended pelvic lymph node dissections. Independent research radiologist reviewed images and rated them on a 5-point scale for the lymph node involvement. Original imaging findings were compared to the independent readings and surgical pathology results.

The patient cohort consisted of 58 participants with a median age of 68 years, and median PSA of 12.4 ng/ml at PET (Figure 1).


Data analysis showed that 31% of study participants had a lymph node involvement. Research demonstrated increased sensitivity (72.2%), specificity (92.5%), and accuracy (86.2%) of 18F-rhPSMA PET compared to the morphological imaging (50.0%, 72.5% and 65.5%) (Figure 2).


The study conducted an additional template-based analysis of the imaging, and 18F-rhPSMA PET succeeded indicators of morphological imaging in terms of sensitivity, specificity, and accuracy.

Research indicated that 18F-rhPSMA PET had more favorable parameters in diagnosing N-staging of prostate cancer compared to the commonly used 68Ga- PSMA PET.

Presented by: Tobias Maurer, MD, Researcher, Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Co-authors: Markus Kroenke,
Alexander Wurzer, Kristina Schwamborn, Lena Ulbrich, Lena Joo, Thomas Horn, Bernhard Haller, Wolfgang Weber, Hans-Jurgen Wester, Matthias Eiber, Munich, Germany

Written by: Hanna Stambakio, BS, Clinical Research Coordinator, Division of Urology, University of Pennsylvania Twitter: @AStambakio at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.